

Tivanisiran

Cat. No.:	HY-132596
CAS No.:	1848224-71-4
Sequence:	RNA, (A-A-G-C-G-C-A-U-C-U-U-C-U-A-C-U-U-C-A), complex with RNA (U-G-A-A-G-U-A-G-A-A-G-A-U-G-C-G-C-U-U) (1:1)
Target:	TRP Channel; Small Interfering RNA (siRNA)
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling; Epigenetics
Storage:	-20°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Tivanisiran

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 100 mg/mL (Need ultrasonic)
In Vivo	1. Add each solvent one by one: PBS Solubility: 25 mg/mL (Infinity mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description	Tivanisiran (SYL1001) is a siRNA used for the study of dry eye disease. Tivanisiran was designed to silence transient receptor potential vanilloid 1 (TRPV1) ^[1] .
In Vitro	In vitro transfection of tivanisiran was shown to produce a 50-60% decrease in TRPV1 mRNA levels ^{[1][2]} . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Anne-Marie Bleau, et al. Development of tivanisiran, a topical siRNA designed to
- [2]. Javier Moreno-Montañés, et al. Tivanisiran, a novel siRNA for the treatment of dry eye disease. Expert Opin Investig Drugs. 2018 Apr;27(4):421-426.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA